Marine Power Systems (MPS) states that it has developed a technology that can harness wind power, wave power or combined wind and wave energy at grid scale. It argues that governments worldwide are looking for alternative sources to meet global energy consumption needs. MPS endeavours to usher in an energy revolution and become a contender in the floating offshore energy market that is set to be worth over $100 billion by 2035. MPS claims to have successfully tested its medium-scaled prototype in the ocean, demonstrating the ease of transportation, deployment, and showcasing the devices ability to generate grid compliant electricity. The company has been awarded a £12.8 million grant by the European Union (EU) to deliver a full scale, grid-connected commercial demonstrator in 2022. It says it will use the investment to conduct its final phase of development and testing before taking its devices to market in Q1 of 2024.
days to go:
Expired
investment:
£4,151,001
Small Beer Brewing Company specialises in brewing classic beer with an Alcohol By Volume (ABV) below 2.8% without any loss in flavour. The company asserts that the beer market is worth £18.4 billion in the UK and over £520 billion globally. In the UK, the 'Low & No' category sits at £450 million. The company aims to be a major contender in this category. It is already exporting its products to Iceland, Singapore, Hong Kong & Spain. The company's stockists include entities like Majestic Wine, Ocado and Waitrose. It will use the investment to fund its expansion both in the UK & foreign markets.
days to go:
Expired
investment:
£750,004
Trackd is a unique, award-winning music platform where artists create and audiences discover. With more than 261,000 users in 161 countries, this simple and intuitive application enables artists to record, collaborate, inspire, and share their ideas around the world. It has featured artists including Dave Stewart (Eurythmics), Valeras, and Blossoms. The app also features a ground-breaking social sharing tools “VirtualVinyl™” and allows video creation directly in the app. Trackd is exploring new and existing partnerships such as Rotor Video and Audio Technica as well as Apple for the next release. The company has already established a stellar team, built a 5-star app and have gained a huge amount of users in the past 3 years. The proceeds will be used for working capital, cash flow requirements, future upgrades, marketing, sponsorship, and events.
days to go:
Expired
investment:
£118,950
C-Major is a medical technology company. It asserts that over 2 million people suffer a Needle Stick Injury (NSI) every year and are at risk of contracting blood-borne viruses such as Hepatitis and HIV. It aspires to resolve this crisis by bringing to market its patented medical device, Controlled Helical Retraction Device, to prevent NSIs. The company argues that the device contains a ‘Helical Track’ mechanism for controlled acceleration of the needle during retraction as well as a ‘Sealed Port’ to minimise any blood splatter. C-Major endeavours to disrupt the $5.5 billion safety syringe market with its product. It is backed by the UK 'Innovation Seed' fund. C-Major will use the investment to complete the final design of its product for manufacture and assembly ahead of a Series A funding round in 2021.
days to go:
Expired
investment:
£211,595
Drop Bear Beer Co. is a specialist brewer of less than 0.5% craft beers. The company asserts that its products are vegan, gluten-free, and low in calories. It has brewed over 160,000 bottles to date. Drop Bear argues that the Global Non-Alcoholic Drinks market was valued at $18 billion in 2020. It aims to be a significant contender in the segment. The company's products are available in six global markets. Drop Bear has won awards ranging from a World Beer Award to a Great British Entrepreneur Award. The company will use the investment to expand its team and build a second dedicated alcohol-free brewery in the UK.
days to go:
Expired
investment:
£325,000
Anastasis Biotec (AB) is a company that is developing a human protein-based product, Syntana-4 (S-4), that inhibits Cancer Stem Cells (CSC) - the growth engine of cancer. The global cancer drug market was at ~$200 billion in 2019. S-4 will initially target use for patients with relapsed prostate cancer which caused 3.8% of global cancer deaths in 2018. The company asserts that S-4 will have low manufacturing costs, making it affordable, enabling ‘mass-market’ sales. AB has raised £450,000 in equity convertible loans and grants in 2019 & 2020, including an Innovate-UK award. It is also aiming to progress S-4 further in collaboration with the University of Chicago’s cancer stem cell therapeutics Research and development (R&D) program. The company will use the investment to complete lab-testing before starting clinical trials.
days to go:
Expired
investment:
£270,543
WhyBuy is a rental platform that allows a user to rent out items or entities he/she may want to another person. WhyBuy asserts that consumers want to be able to access items for brief periods, and the company aims to be the go-to provider in this segment. It endeavours to save time, space, money and the environment through its business model that is backed by a 100% electric delivery fleet. The company has tested its supply chain to ensure orders are placed despite COVID-19 restrictions. Its app has seen 8000+ downloads from mid-June to end-July 2020 at just over £3 per acquired download across the App Store and Google Playstore. It will use 75% of the investment for marketing, 5% to expand its electric fleet, and 15% as stock and overhead expenses.
days to go:
Expired
investment:
£309,260
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
AdLaunch is an online video maker tool aimed at social media advertising creation. Using its patented AI-powered video generation technology, it enables businesses to create multiple high-quality videos, realtime previews and edit videos in the browser itself. This helps companies undertake online video advertising almost instantaneously within their respective budgets. AdLaunch has 11,000 users in over 130 countries worldwide. It has made 1.4 million pre-licensed HD videos and high-quality photos. The company aims to become synonymous with creating data-driven video ads and video campaigns. AdLaunch was awarded the 'Third Prize' at the Slush 100 pitch competition out of 2650 companies. it also secured three government R&D grants totaling £219,000 from the Business Finland - the Finnish Innovation Agency. AdLaunch is partnering with AppSumo which has a user base of 730,000 registered newsletter readers. With the proceeds, the company will develop its video generator and invest £8000 per month on Google, Facebook, and YouTube advertising to accelerate its customer acquisition.
days to go:
Expired
investment:
£85,278
MedicSpot is a healthcare company that is aiming to revolutionise healthcare delivery by combining the advantages of online and offline care. The company provides patients at designated hospitals with diagnostic tools like a stethoscope, oximeter, blood pressure monitor and thermometer which, in turn, is connected to the MedicSpot network. Onboard General Physicians (GPs) engage in live sessions with patients, guide them on how to use the tools, and perform a variety of diagnoses like listening to a patient’s heart and lungs, looking down their throat and into their ears, taking their blood pressure and oxygen readings, and measuring their body temperature. The company is also expanding into another subsidiary, Arc Health, which it claims will perform the aforementioned tasks with more efficiency and accuracy. The company will use the investment to increase the number of Medicspot clinics to 1,000, gain further NHS market share, launch a corporate business model and allow international pilots to take place.
days to go:
Expired
investment:
£1,048,396
